DAVENPORT & Co LLC raised its position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) by 44.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 157,105 shares of the company’s stock after acquiring an additional 48,560 shares during the period. […]
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its target price reduced by HC Wainwright from $79.00 to $66.00 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2023 earnings at ($1.81) EPS, Q2 2023 […]
Hennion & Walsh Asset Management Inc. raised its position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) by 14.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 39,185 shares of the company’s stock after acquiring an additional 4,954 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in BioXcel Therapeutics were […]
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to.
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.